Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial

This publication has 31 references indexed in Scilit:

• Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy
  Critical Reviews in Oncology/Hematology, 2024
• Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
  The Lancet, 2023
• Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia
  Cancer Cell, 2022
• Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
  Blood Cancer Journal, 2022
• Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification
  American Journal of Hematology, 2022
• Targeting mitochondrial respiration for the treatment of acute myeloid leukemia
  Biochemical Pharmacology, 2020
• PIM kinases alter mitochondrial dynamics and chemosensitivity in lung cancer
  Oncogene, 2020
• Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
  The Lancet Oncology, 2019
• Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML
  New England Journal of Medicine, 2018
• Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with aFLT3Mutation
  New England Journal of Medicine, 2017